BIO Statement on House GOP Tax Reform BillNov 2 2017
Washington, DC (November 2, 2017) – Biotechnology Innovation Organization (BIO) Jim Greenwood released the following statement today regarding the Tax Cuts and Jobs Act:
“BIO applauds Chairman Brady and the House Ways & Means Committee for their dedication to pro-growth tax reform. Tax reform presents a unique, historic opportunity to stimulate American investment, support job creation, and promote life-saving innovation. The Tax Cuts and Jobs Act would lower America’s corporate tax rate, maintain the R&D Tax Credit, and move the U.S. to a territorial tax system, which will make the U.S. more competitive on the world stage and support domestic manufacturing and job creation. This reform is vital to maintaining American leadership in biotechnology innovation.
|
|
BIO Applauds MLP Parity Act, Thanks Senate and House SponsorsOct 25 2017
The bipartisan Master Limited Partnerships Parity Act of 2017 would level the playing field in the tax code by giving investors in renewable energy projects access to a decades-old corporate structure with a tax advantage now available only to fossil fuel projects.
|
|
BIO, Member Companies Ask Congress to Reauthorize Section 9003 Program in Farm BillOct 19 2017
BIO and 66 renewable chemical producers today asked leaders of the House and Senate Committees on Agriculture to reauthorize the Farm Bill’s Biorefinery, Renewable Chemical, and Biobased Manufacturing Assistance Program (Section 9003) and “fully and unconditionally allow renewable chemical standalone manufacturing facilities” to receive Section 9003 Program loan guarantees without requiring production of advanced biofuels.
|
|
BIO Applauds Senate Introduction of Renewable Chemicals Tax CreditOct 19 2017
BIO thanks Sen. Debbie Stabenow (D-MI) and co-sponsors Sens. Tammy Baldwin (D-WI), Susan Collins (R-ME), Chris Coons (D-DE), and Al Franken (D-MN) for introducing the Renewable Chemicals Act of 2017 (S.1980), which would create a targeted, short-term tax credit for production of qualifying renewable chemicals or investment in production facilities.
|
|
BIO Investor Forum ConcludesOct 18 2017
The BIO Investor Forum finished today after hosting two days of expert-led panel discussions, fireside chats, over 165 company presentations and more than 2,750 individual meetings arranged through BIO One-on-One Partnering — a 26 percent increase over last year. The event was attended by more than 1,000 representatives of private and early stage biotech companies, leading investment firms, research organizations and others who came together to foster the development of new medical treatments and to grow the industry’s pipeline.
|
|
Hill Leaders Urge Support for Reg System that Supports Ag InnovationOct 17 2017
USDA, FDA and EPA must “coordinate with each other and stakeholders”
Washington, D.C. (October 17, 2017) – Under the leadership of Reps. Neal Dunn (R-Fla.) and Jimmy Panetta (D-Calif.), 79 Members of the House of Representatives signed on to a letter urging for a “consistent, science-based, risk-proportionate regulatory system” for agricultural biotechnology.
|
|
BIO Statement on California Governor Brown Signing Drug Price Reporting & Transparency BillOct 9 2017
BIO will continue to oppose legislative efforts, such as SB 17, that harm patient access to needed care by undermining competition, disrupting existing drug product availability, or stifling investment in the innovation ecosystem through misguided government intrusion.
|
|
BIO Congratulates SAB Biotherapeutics on Pharm GroundbreakingOct 5 2017
Sioux Falls, S.D. 80-acre biological pharm is first-of-its kind
Washington, D.C. (October 5, 2017) – Sioux Falls, S.D.-based SAB Biotherapeutics, Inc. (SAB), celebrated construction of their 80-acre biopharmaceutical production pharm operation with a groundbreaking ceremony today in Lincoln County.
|
|
Sixth Annual BIO Patient and Health Advocacy Summit Concludes TodayOct 3 2017
The 2017 Patient and Health Advocacy Summit wrapped up today, having offered the nearly 240 patient groups, companies and organizations new ways to connect, strategize, learn and partner. For the past six years, the BIO Patient and Health Advocacy Summit has brought together a diverse group of organizations including patient advocacy, health care providers, academia, government, think tanks, professional societies and the biotechnology industry to focus on bringing the patients’ voice to the drug development process.
|
|
BIO to Offer Complimentary Access to One-on-One Partnering™ During J.P. Morgan Healthcare Conference (“JPM Week”)Sep 28 2017
BIO will offer complimentary access to its proprietary BIO One-on-One Partnering™ during "JPM" week January 7-11, 2018
|
